Archived articles

Drug policy

Changemakers
Policy solutions to combat addiction
Published Aug 16, 2023
Jacqueline Hackett, who earned a MPH from the Johns Hopkins Bloomberg School of Public Health, serves as deputy chief of staff for the White House Office of National Drug Control Policy
Q+A
Insights on FDA's controversial approval of Alzheimer's drug
Published June 21, 2021
Supriya Munshaw, an expert in drug commercialization, discusses what factors went into the FDA approval of aducanumab, a drug known by the brand name Aduhelm
Q+A
The path forward for legal medical mushrooms
Published Dec 2, 2020
Johns Hopkins researcher Matthew Johnson discusses the future for psychedelics research in light of Oregon's measure to legalize psilocybin for clinical use
Drug policy
Five things to know about overdose prevention sites
Published Feb 12, 2020
Research suggests that the facilities are safe and cost effective, but bringing them to the U.S. has been controversial
Drug policy
A look inside early efforts to create safe consumption sites in the U.S.
Published Feb 22, 2019
Study analyzes early policy efforts, identifies challenges and paths forward / School of Public Health
Medical marijuana
A sea change in CBD drug policy?
Published Oct 2, 2018
The DEA announced a shift Friday that clears the way for the first prescription drug derived from the marijuana plant to make its way to market